A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer.

Trial Profile

A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Capecitabine (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil; Trastuzumab
  • Indications Early breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FinXX
  • Most Recent Events

    • 07 Jun 2016 10-year survival results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 09 Dec 2010 Final 5-year analysis presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS).
    • 09 Dec 2010 Final 5-year exploratory analyses from the subgroup of patients with triple-negative early breast cancer were presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top